LifeSci Capital Initiates Coverage of Bellus Health
Conducting a Phase III Trial of KIACTA for AA Amyloidosis; Data Expected Mid-2016
Report Available here: www.lifescicapital.com/equity-research/bellus-health/
NEW YORK, NY / ACCESSWIRE / July 1, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Bellus Health (TSX:BLU.TO), a clinical-stage biotechnology company focused on developing disease-modifying therapies for AA amyloidosis, sarcoidosis, and Shiga toxin producing E. coli induced hemolytic uremic syndrome (STEC-HUS).
Bellus is developing its lead candidate KIACTA for the treatment of AA amyloidosis, a rare, life-threatening disease mainly affecting the kidneys that can lead to end-stage renal disease. There are no approved therapies for this indication and the long-term prognosis for affected individuals is poor. Bellus is currently conducting a pivotal Phase III study with KIACTA in partnership with Auven Therapeutics and expects to report results in the middle of 2016. Two additional programs are expected to enter Phase II in the near-term, including KIACTA for sarcoidosis and an antibody program, Shigamab, for STEC-HUS.
In a 29 page Initiation Report, LifeSci Capital explains the unmet medical need in treating AA amyloidosis, Bellus's Phase III development in partnership with Auven Therapeutics, and the orphan disease market.
Jerry Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Bellus Health's as developments occur.
The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.
About LifeSci Capital:
LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.
Analyst Contact:
Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com
SOURCE: LifeSci Capital, LLC
